Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

Cancer Immunology Research

Volumn 3, Issue 11, 2015, Pages 1201-1206

  Glitza, Isabella C ^a   Haymaker, Cara ^a   Bernatchez, Chantale ^a   Vence, Luis ^a   Rohlfs, Michelle ^a   Richard, Jessie ^a   Lacey, Carol ^a   Mansaray, Rahmatu ^a   Fulbright, Orenthial J ^a   Ramachandran, Renjith ^a   Toth, Christopher ^a   Wardell, Seth ^a   Patel, Sapna P ^a   Woodman, Scott E ^a   Hwu, Wen Jen ^a   Radvanyi, Laszlo G ^a   Davies, Michael A ^a   Papadopoulos, Nicholas E ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; INTERLEUKIN 2;

ADULT; ARTICLE; BRAIN METASTASIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CHILL; CRANIOTOMY; CUTANEOUS MELANOMA; DISEASE COURSE; DRUG SAFETY; HEADACHE; HUMAN; INTRACRANIAL HYPERTENSION; LEPTOMENINGEAL DISEASE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MENINX DISORDER; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; SENTINEL LYMPH NODE BIOPSY; STEREOTACTIC RADIOSURGERY; TUMOR ASSOCIATED LEUKOCYTE; VOMITING; CEREBROSPINAL FLUID; FATALITY; INTRASPINAL DRUG ADMINISTRATION; MELANOMA; MENINGEAL CARCINOMATOSIS; SECONDARY; TRANSPLANTATION;

CYTOKINES; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; INJECTIONS, SPINAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MENINGEAL CARCINOMATOSIS; MIDDLE AGED;

EID: 84957588938     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0071     Document Type: Article

References (14)

1. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998;88:11-20.
2. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011;117:1687-96.
3. Raizer JJ, Hwu WJ, Panageas KS,Wilton A, BaldwinDE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro Oncol 2008;10:199-207.
4. Stapleton S, Blaney S. New agents for intrathecal administration. Cancer Invest 2006;24:528-34.
5. Papadopoulos N, Eton O, Bedikian AY. The role of intrathecal (IT) use of interleukin-2 (IL-2) in the treatment of leptomeningeal disease (LMD) in patients (pts) with melanoma. Proc Am Soc Clin Oncol 2002;21:353a.
6. Pape E, Desmedt E, Zairi F, Baranzelli MC, Dziwniel V, Dubois F, et al. Leptomeningeal metastasis in melanoma: A prospective clinical study of nine patients. In Vivo 2012;26:1079-86.
7. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 2002;94: 2675-80.
8. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
9. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18(24):6758-70.
10. Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, et al. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma. Clin Cancer Res 2001;7:917s-24s.
11. List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: Rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res 1992;52:1123-8.
12. Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: A case report. Melanoma Res 2013;23:175-8.
13. Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): A case report. J Med Case Rep 2012;6:131.
14. Bot I, Blank CU, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 2012;259:1976-8.